Electrocardiographic assessment for therapeutic proteins--scientific discussion.

Published

Journal Article (Review)

Electrocardiographic monitoring is an integral component of the clinical assessment of cardiac safety of all compounds in development. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline recommends a dedicated study to evaluate drug-induced effects on cardiac repolarization ("thorough QT/QTc study"). There has been limited published information on QT interval changes secondary to therapeutic proteins; however, in theory, biologic therapies may affect cardiac electrical activity either directly or indirectly. This article summarizes scientific discussions of members of the Cardiac Safety Research Consortium and includes possible approaches to consider for the clinical evaluation of drug-induced QT prolongation in development programs of therapeutic proteins.

Full Text

Duke Authors

Cited Authors

  • Rodriguez, I; Erdman, A; Padhi, D; Garnett, CE; Zhao, H; Targum, SL; Balakrishnan, S; Strnadova, C; Viner, N; Geiger, MJ; Newton-Cheh, C; Litwin, J; Pugsley, MK; Sager, PT; Krucoff, MW; Finkle, JK

Published Date

  • October 2010

Published In

Volume / Issue

  • 160 / 4

Start / End Page

  • 627 - 634

PubMed ID

  • 20934555

Pubmed Central ID

  • 20934555

Electronic International Standard Serial Number (EISSN)

  • 1097-6744

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2010.07.001

Language

  • eng

Conference Location

  • United States